US/UK/Canada

Share

Contacts

  • Cyxone AB
    Adelgatan 21 SE 211 22 Malmö
    +46 708882172
    +46 708882172
    http://www.cyxone.com

    • Quotes

    We are happy to announce the positive study outcomes, an instrumental part of the preparations for the Phase 2 study in RA patients set to start late next year. Equally, we are eagerly looking forward to the imminent initiation of our clinical study of Rabeximod in Covid-19 patients. Combined with the new patent applications recently filed, with potential to substantially prolong market exclusivity, and with a stockpile of drug substance enabling further clinical studies beyond those currently in the pipeline, we stand with a strong foothold in future partnering negotiations. All in all, Cyxone is well-positioned for the development of safe and innovative treatments toward serious immune system disorders.
    Tara Heitner, CEO, Cyxone
    After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.
    Malin Berthold, Head of Project Management at Cyxone
    This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
    Kjell G. Stenberg, CEO of Cyxone
    The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.
    Kjell G. Stenberg, CEO of Cyxone
    Pick a time period -

    Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod

    Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery. The study will include 300 patients at clinical centers in Poland, Slovakia and up to three additional countries in Europe. Cyxone expects to announce preliminary results in the third quarter of 2021.Cyxone recently announced that the company had received regulatory approval to initiate a

    First Berlin Equity Research publishes independent analysis of Cyxone

    Cyxone (publ.), a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announces today that the research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first nine months of 2020 and a pipeline update. In the analysis, which was published on 17 December 2020, First Berlin reviewed the company’s potential with an expected but continued positive outcome. The report in English can be read in its entirety on the Cyxone’s website. Contact Tara Heitner, CEOTel:

    Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA

    Cyxone (publ.), a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announced today that the company has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) pertaining to its drug candidate Rabeximod. The application follows on a productive pre-IND meeting with the authority, where valuable advice was received on inter alia the protocol for its imminent European Phase 2 clinical study in moderate Covid-19. The IND covers the development of Rabeximod in Covid-19 and other indications, such as

    BioStock: Regulatory approval and up-listing for Cyxone

    Activity is high in Cyxone. The biotechnology company recently received approval to start a phase II study in Poland with Rabeximod in patients suffering from moderate Covid-19. They have also announced the intention to apply for listing of their share on Nasdaq Stockholm's main list. BioStock reached out to CEO Tara Heitner, who shares her thoughts on the timing of the up-listing and how Rabeximod can open up for the treatment of respiratory diseases, beyond Covid-19, caused by viral infections.Read the full interview with Tara Heitner at biostock.se: https://www.biostock.se/en/

    Cyxone has decided to apply for a listing of its share on Nasdaq Stockholm Main Market

    Cyxone (publ.) announced today that its Board of Directors has decided to apply for a listing of the company’s share on Nasdaq Stockholm Main Market. The company will prepare to submit an application in the first quarter of 2022. Cyxone is currently listed on Nasdaq First North Growth Market.Cyxone develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Its most advanced project, Rabeximod, is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis

    Cyxone receives regulatory approval to initiate a clinical Phase 2 study with Rabeximod in Covid-19 patients

    Cyxone (publ.) announced today it has received approval from the regulatory authority and the ethics committee in Poland to initiate a Phase 2 clinical trial with Rabeximod in moderate Covid-19 patients. The oral treatment is intended to prevent the progression to acute respiratory distress symptoms (ARDS) caused by virus-related overactivation of the immune system. Preliminary results are expected in the third quarter of 2021.Most individuals infected with Covid-19 experience only mild symptoms. However, in some patients there is a risk that the immune system overreacts, triggering a

    First day of trading with warrants of series TO4

    As previously communicated, Cyxone AB (publ) (“Cyxone” or the “Company”) has resolved to allocate one (1) warrant of series TO4 to the Company’s existing shareholders for every twenty-eight (28) shares owned on the record date of November 19, 2020. The Warrants will, to some extent, compensate the current shareholders in the Company for the dilution that the previously conducted directed issue of shares and warrants entails. In this context, the Company simultaneously announces that the first day for trading with warrants of series TO4 on Nasdaq First North Growth Market has been set to

    Record date for the distribution of warrants of series TO4 to current shareholders is set to November 19, 2020

    On November 10 2020, the board of directors of Cyxone AB (publ), (“Cyxone” or the “Company”) decided to carry out a Directed Issue (the “Directed Issue”), and to issue warrants of series TO4 to the current shareholders of Cyxone who on the record date holds shares in the Company. The warrants will, to some extent, compensate the current shareholders in the Company for the dilution in the Directed Issue.The record date to receive warrants of series TO4 has been set to November 19, 2020. Therefore, the last day of trading in the Company’s share including the right to receive warrants of

    Cyxone presents at BioStock Life Science Summit 17-18 November 2020

    CEO Tara Heitner will present the latest updates in Cyxone on 18 November at 14.35 at the online event BioStock Life Science Summit. Information about the event together with the agenda is found on the event’s webpage . Follow the presentation live here .Contact Tara Heitner, CEOTel: +46 70 781 88 08Email: tara.heitner@cyxone.comAdelgatan 21211 22 Malmö, Sweden About Cyxone Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases

    BioStock: Cyxone attracts funding and files for new patents

    In a short period of time, biotech company Cyxone has secured some 40 MSEK to fund the phase II study of Rabeximod in Covid 19-patients which is planned to start before year-end as well as other development activities. The capital raise has been conducted in two separate transactions, including a fully subscribed directed share issue of approximately 19 MSEK announced on November 10. Further, the company recently announced positive toxicological results for Rabeximod and has now also filed for extended patent protection with the European Patent Office (EPO).Read the full article about

    Interim Report 1 January to 30 September 2020

    Summary of the interim reportFirst nine months (January 1st to September 30th, 2020) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -36 978 (-26 122) · Earnings per share -0,75 (-0,70) · Cash and cash equivalents as of September 30th KSEK 44 587 (12 307) · Equity ratio as of September 30th 64,1 (83,0) % Third Quarter (July 1st to September 30th, 2020) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -12 608 (-12 710) · Earnings per share -0,25 (-0,34) Significant events during the third quarter of 2020 · Cyxone

    The board of directors of Cyxone have decided to carry out a directed issue of units of approximately SEK 19 million and an issue of warrants to current shareholders

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.Cyxone AB (publ) (”Cyxone” or the ”Company”) have carried out a directed issue of 4,075,000 units, where each unit consists of one (1) share and one (1) warrant of series TO4, to

    Cyxone intends to carry out a directed issue of units

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.Cyxone AB (publ) (”Cyxone” or the ”Company”) today announces its intention to carry out a directed issue of units of approximately SEK 19 million, consisting of one (1) share and one (

    Cyxone files patent application to extend exclusivity of Rabeximod

    Cyxone (publ.) announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course. An approval of the application will strengthen the company’s intellectual property portfolio and generate a longer market exclusivity for Rabeximod.Cyxone develops Rabeximod, a potentially disease modifying drug candidate for chronic diseases of the immune system as well as for critical conditions such as virally induced acute respiratory disorders. The candidate drug is subject to two

    Cyxone announces positive results from regulatory toxicology studies of Rabeximod

    Cyxone (publ.), a Swedish biotech company developing disease modifying therapies for disorders of the immune system, today announced that the six-month regulatory toxicology studies of its drug candidate Rabeximod has been successfully concluded. A read-out of the study results shows a favorable safety profile for Rabeximod, thus enabling longer clinical studies in patients up to six months. Cyxone will now take the next step toward the initiation of a Phase 2 study in rheumatoid arthritis patients.The concluded six-month toxicology studies in two species are obligatory evaluations demanded

    BioStock: Cyxone announces expanded plans for Rabeximod

    The Swedish biotech company Cyxone recently announced expanded plans for the development of their drug candidate Rabeximod. Four new patent applications were filed earlier this year greatly extending the potential for market exclusivity. This has led to a revision of the Rabeximod development plan. The number of possible applications and therefore the value of Rabeximod has increased significantly. The Covid-19 global pandemic continues with an imminent and immense need for better treatments where Cyxone believes that Rabeximod can make a difference. Cyxone will conduct a phase II study with

    BioStock: Awareness around arthritis raised for the 24:th consecutive year

    October 12th is World Arthritis Day, a global awareness day for rheumatic and musculoskeletal diseases. Malmö based Cyxone’s drug candidate Rabeximod is a disease modifying treatment for rheumatoid arthritis, a disease affecting well over 4 million patients worldwide. The goal is to provide patients with safe but effective treatment that can be conveniently taken and not only treat symptoms but importantly stop damage to the joints before extensive irreversible damage occurs. The company is in the process of designing a phase II trial for Rabeximod which is anticipated to start in the latter

    Cyxone further strengthens the team to reinforce the development projects

    Cyxone (publ.), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, today announced the recruitment of Sally Abdelmoaty as Project Manager to focus on the next step in the development of Cyxone's drug portfolio. The recruitment will strengthen Cyxone’s capabilities in non-clinical drug development. Sally Abdelmoaty will primarily focus on the T20K project but will contribute with her deep scientific knowledge to all projects.Sally Abdelmoaty holds a PhD in Pharmacology and Toxicology from Karolinska Institutet, Solna, Sweden and Faculty of Pharmacy,

    Cyxone receives in total SEK 21.8 million in proceeds from fully utilized investment option agreement with Dr. Kalev Kask

    Cyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that the investment option agreement with Dr. Kalev Kask has been fully utilized through a third and final utilization of the investment option. The three directed share issues carried out under the agreement brings the company a gross proceed of SEK 21.8 million in total, whereof, SEK 1.8 million has already been received through earlier utilizations. This will cover most of the costs for the planned phase 2 clinical study of Rabeximod in Covid-19 patients. This

    BioStock: Cyxone has gathered new force

    Biotech company Cyxone has had a busy summer. In June Tara Heitner took over as the new CEO and has since strengthened the team and the internal therapeutic expertise through the recruitment of Christin Arrhenius Bokedal as Head of Development and presented Maarten Kraan and Rikard Holmdahl as the company’s senior scientific advisors. BioStock reached out to the two senior advisors to hear their views on their new positions.Read the full article about Cyxone at BioStock.se: https://www.biostock.se/en/cyxone-has-gathered-new-force/ This is a press release from BioStock - Connecting

    Cyxone revises the development plan for Rabeximod

    Cyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it has initiated a process to optimize the development plan for Rabeximod. This initiative is based on valuable input from the company’s new senior medical advisors, updated market intelligence and the opportunity to prolong market exclusivity through newly filed patent applications. In parallel, the company is preparing a phase 2 clinical study of Rabeximod in Covid-19 patients, with a potential initiation already in the fourth quarter of 2020.With a new CEO

    Cyxone raises SEK 1 million in a second directed share issue under the agreement with Dr Kask to jointly develop a new treatment of Covid-19

    Cyxone AB (publ), a Swedish biotech company engaged in developing new treatments for autoimmune diseases, has today resolved on a directed share issue of 214,858 shares, with a net proceed of SEK 1 million. The share issue is made under the investment option agreement with Dr Kalev Kask, which has been put in place to jointly develop a new treatment for Covid-19.The board of directors of Cyxone has resolved on a directed share issue in accordance with the investment option agreement that the Company entered into with Dr Kalev Kask, which was described in more detail in the Company’s press

    BioStock: Tara Heitner is ready to take Cyxone to the next level

    Canadian Tara Heitner took office as the new CEO of Cyxone on June 1. The company develops immunomodulating drugs for autoimmune diseases and the portfolio consists of two clinical programmes. Rabeximod is developed as a new therapy for rheumatoid arthritis while T20K is developed for multiple sclerosis. Tara Heitner came to the BioStock Studio and told us about her background, her first impressions of Cyxone and what she already has achieved in her new position.Watch the interview with Tara Heitner at biostock.se: https://www.biostock.se/en/biostock-studio-tara-heitner-is-ready-to-take-

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media